PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has been granted an exclusive patent by the US Patent and Trademark Office (USPTO) on CF101 for the treatment of RA, valid until 2023.
